Qing Li

Qing Li

Auto-generated profile, based on publicly available information

Qing Li

Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Science China Technological Sciences
Verified
Journal Article
Closed access
PDF file
GLGuofei Li
Guofei Li
QLQing Li
Qing Li
YWYunJie Wu
YunJie Wu
PXPengYa Xu
PengYa Xu
JLJianwei Liu
Jianwei Liu

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
QLQing Li
Qing Li
CSChengxiang Song
Chengxiang Song
ZWZisong Wei
Zisong Wei
JLJunli Li
Junli Li
HZHao Zhou
Hao Zhou
CMChen Mao
Chen Mao
Objective: Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition driven by the osteogenic differentiation of valve interstitial cells (VICs), with no effective drug therapies currently available. Hence, our objective is to investigate the impact of thrombospondin‐1 (TSP‐1) silencing on CAVD progression. Methods: In vitro experiments were employed using human primary VICs with TSP‐1 knockdown, cultured in osteogenic induction medium, and followed by analyses including western blot, alkaline phosphatase staining, alizarin red staining, immunofluorescence, and flow cytometry. In vivo experiments used two murine models of CAVD to determine the role of TSP‐1 silencing on aortic valve calcification. Results: We observed that silencing of TSP‐1 reduced the osteogenic differentiation of VICs. Subsequent experiments demonstrated that TSP‐1 knockdown suppressed nuclear factor‐ κ B (NF‐ κ B)–mediated inflammation during osteoblastic differentiation of VICs. Consistent findings were also observed in two murine models of CAVD. Conclusions: The present study has shown that TSP‐1 silencing could mitigate the development of CAVD by inhibiting NF‐ κ B‐mediated inflammation. We propose that targeting TSP‐1‐mediated NF‐ κ B pathway could provide a potential therapeutic method for treating CAVD.